Company intelligence / Profile preview

1ST Biotherapeutics

Yongin-si, Gyeonggi-do, South Korea1stbio.com ↗

Ownership: Private
Employees: ~24
Development stage: Phase 1

Overview

Currently conducting Phase 1/2 clinical trials for FB-849 (HPK1 inhibitor) for advanced solid tumors, and Phase 1 trials for FB-101 and FB-418 for ALS

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Small molecule drugsAntibody drug conjugates (ADC)TIL therapyDiagnostic radiopharmaceuticals
Industry: Biotech

Drug pipeline

10 assets

FB849

9 more assets in the full pipeline.

Request access →

Partnerships

The Michael J. Fox Foundation's LITE ProgramMerck (for KEYTRUDA combination study)

Beyond the preview

Go deeper on 1ST Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1ST Biotherapeutics.

Explore the full profile